Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
4 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Ovarian Mixed Germ Cell Tumor, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Brain Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Neuroblastoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
busulfan, melphalan, topotecan hydrochloride, laboratory biomarker analysis, filgrastim, autologous hematopoietic stem cell transplantation, pharmacological study, autologous bone marrow transplantation
Drug · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Duarte, California
Conditions
Brain and Central Nervous System Tumors
Interventions
Not listed
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 5 more
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, lobradimil
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
207
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 152 more
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
O6-benzylguanine, temozolomide, filgrastim, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
palbociclib isethionate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
4 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Melanoma, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Arcadia, California
Conditions
Metastatic Medulloblastoma, High Risk Supratentorial PNET, Metastatic PNET
Interventions
Carboplatin, Vincristine, 24 Gy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 25 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
vorinostat, isotretinoin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
Interventions
Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
0 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts
Conditions
Brain and Central Nervous System Tumors
Interventions
MK-0752
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, vincristine, autologous hematopoietic stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2023
U.S. locations
4
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Conditions
Cancer
Interventions
cyproheptadine hydrochloride, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma
Interventions
Cediranib Maleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, etoposide, vincristine sulfate, adjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
14
States / cities
Tampa, Florida • Chicago, Illinois • Urbana, Illinois + 9 more
Conditions
Brain and Central Nervous System Tumors
Interventions
Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy, Intermediate-Risk Therapy
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 5 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • Saint Paul, Minnesota + 2 more
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity
Interventions
Donepezil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Central Nervous System Germ Cell Tumor, Adult Choroid Plexus Tumor, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Medulloblastoma, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Meningeal Melanocytoma
Interventions
EF5, conventional surgery, positron emission tomography, fluorine F 18 EF5, pharmacological study
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Glioblastoma, Astrocytoma, Pineoblastoma, Rhabdoid Tumor, Supratentorial Neoplasms
Interventions
Stem Cell Transplant
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
18 Months to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Conditions
Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide Phosphate, Isotretinoin, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Thiotepa, Vincristine Sulfate, Vorinostat
Radiation · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Months to 47 Months
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 10 more
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Medulloepithelioma, Childhood Meningioma, Childhood Mixed Glioma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Childhood Oligodendroglioma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
iodine I 131 monoclonal antibody 3F8
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
New York, New York
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Tumor, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Recurrent Adult Brain Tumor
Interventions
yoga therapy, questionnaire administration, quality-of-life assessment
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina